Alzheimer’s: Slowing the Decline Is Not Good Enough
By Dr. Garland Glenn, DC, PhD, IFM, AFMC
Founder and Clinical Director, The Carroll Institute, Sarasota, Florida
If someone you love is struggling with memory loss, confusion, word-finding difficulties, or mental fog, you may have heard that Alzheimer’s disease is irreversible. You may also have heard that the best available treatments can only slow its progression.
But getting worse more slowly is still getting worse.
And that’s not good enough.
For decades, Alzheimer’s research has focused heavily on amyloid plaque. Consequently, pharmaceutical companies have invested billions of dollars developing medications designed to remove amyloid from the brain.
Today, Leqembi (lecanemab) and Kisunla (donanemab) can accomplish that biological goal.
However, neither drug has demonstrated that it can restore lost memory or reverse Alzheimer’s dementia. Furthermore, recent research raises serious questions about their long-term effectiveness, brain-volume changes, and potentially life-threatening complications.
Meanwhile, neuroscience has identified another critical process involved in cognitive decline: chronic neuroinflammation and dysfunction of the brain’s immune system.
For years, I have believed that understanding and addressing the factors driving brain inflammation represents a far more comprehensive strategy than focusing exclusively on amyloid plaque.
At The Carroll Institute in Sarasota, Florida, we approach cognitive decline by asking a different question:
What is causing this patient's brain to deteriorate, and which contributing factors can we identify and correct?
That question forms the foundation of the Carroll Cognitive Method™.
Alzheimer's Disease Is More Than an Amyloid Problem
The traditional amyloid hypothesis proposes that the accumulation of amyloid-beta plays a central role in Alzheimer's disease.
However, Alzheimer's is far more complicated than the presence of one abnormal protein.
The disease also involves chronic inflammation, immune dysfunction, mitochondrial impairment, abnormal tau proteins, vascular changes, and damage to the connections between neurons.
These processes interact with one another.
For example, amyloid accumulation can activate inflammatory pathways. Meanwhile, chronic inflammation may interfere with the brain's ability to clear amyloid and maintain healthy neural connections.
Consequently, the relationship between amyloid and neurodegeneration is not simply a one-way process.
Research has also identified amyloid deposits in some older adults who maintained normal cognitive function during life.
That observation raises an important question.
If amyloid plaque alone determines cognitive decline, why do some people with substantial plaque remain cognitively normal?
The answer is that amyloid is only one part of a much larger biological picture.
Therefore, removing plaque does not necessarily correct the processes responsible for declining brain function.
The Swollen Ankle Problem: Treating the Sign Instead of the Cause
Imagine someone severely sprains an ankle.
Within hours, the ankle becomes swollen.
Now imagine a medication that removes the swelling but leaves the damaged ligaments untouched.
The ankle might look better. However, the underlying injury remains.
No orthopedic surgeon would confuse reducing swelling with repairing damaged tissue.
I believe this analogy illustrates the limitations of focusing exclusively on amyloid plaque.
Amyloid may contribute to Alzheimer's pathology. However, removing it does not automatically repair damaged neurons, restore lost synapses, or correct metabolic dysfunction.
Furthermore, plaque removal does not necessarily resolve the inflammatory environment that contributes to ongoing injury.
Therefore, the better question is not simply how to remove amyloid.
The better question is why the brain is struggling in the first place.
That distinction matters because many factors influencing brain health can be investigated, and some can be modified.
The Brain's Immune System: Understanding Glial Cell Activation
One of the most important developments in neuroscience involves our understanding of the brain's immune system.
For many years, researchers concentrated primarily on neurons.
However, neurons represent only part of the brain's cellular population.
Other cells, collectively called glial cells, perform essential functions that support and protect the nervous system.
Among these cells, microglia serve as the brain's resident immune defenders.
Under healthy conditions, microglia constantly monitor their surroundings.
They remove cellular debris, respond to injury, help maintain healthy synapses, and support the brain's normal functioning.
However, these same cells can contribute to damage when inflammatory signaling becomes excessive or prolonged.
This process is called microglial activation.
When the brain experiences infection, injury, metabolic stress, or other disturbances, microglia respond by releasing inflammatory signals.
Initially, this response may protect the brain.
However, chronic activation can create a damaging cycle of inflammation, oxidative stress, and neuronal injury.
Over time, dysregulated microglia may also contribute to the inappropriate removal of healthy synapses.
Because synapses allow neurons to communicate, their loss can profoundly affect memory and cognitive performance.
The brain's immune system can protect neurons, but persistent immune dysfunction can also contribute to their destruction.
What Is Microglial Priming, and Why Does It Matter?
Another important concept is microglial priming.
Priming occurs when previous exposure to inflammatory or stressful conditions changes how microglia respond to future challenges.
For example, aging, chronic metabolic dysfunction, and certain inflammatory conditions may alter microglial behavior.
Consequently, a later challenge can produce a stronger inflammatory response than it otherwise would.
This helps explain why multiple health problems may interact to influence cognitive decline.
Consider someone with insulin resistance, poor sleep, vascular disease, and chronic inflammation.
Each condition may place additional stress on the brain.
Together, they may create an environment in which immune regulation becomes increasingly difficult.
Furthermore, inflammation and neuronal injury can reinforce one another.
As neurons become damaged, they release signals that activate nearby immune cells.
Those activated cells may then release additional inflammatory molecules.
Consequently, a self-perpetuating cycle can develop.
Researchers continue to investigate exactly how these processes contribute to Alzheimer's disease. Nevertheless, microglial activation and priming have become important areas of neurodegenerative research.
Why Metabolic Health Matters to the Brain
The brain requires enormous amounts of energy.
Neurons depend on a continuous supply of fuel to maintain communication, memory, and other essential functions.
Meanwhile, microglia require energy to perform their protective duties.
Much of this energy comes from mitochondria, the structures inside cells responsible for producing usable cellular energy.
However, mitochondrial dysfunction can interfere with normal cellular activity.
Metabolic problems such as insulin resistance and diabetes can also contribute to inflammatory signaling.
Consequently, researchers increasingly recognize important connections among metabolism, immune function, and brain health.
For example, insulin resistance is associated with an increased risk of cognitive decline.
Likewise, cardiovascular disease and poor vascular health can interfere with the brain's oxygen and nutrient supply.
Sleep disorders may worsen these problems by disrupting restorative processes and increasing physiological stress.
Therefore, cognitive decline cannot always be understood by looking at the brain in isolation.
The health of the brain depends, in part, on the health of the entire body.
This is why we believe evaluating metabolic and physiological contributors deserves a central role in cognitive care.
What Do Leqembi and Kisunla Actually Accomplish?
Leqembi and Kisunla are monoclonal antibodies that target amyloid-beta.
Both medications can substantially reduce amyloid deposits.
However, their pivotal clinical trials demonstrated modest slowing of cognitive decline rather than restoration of lost function.
For example, the original lecanemab trial reported approximately 27% less decline than placebo over 18 months.
Although that percentage sounds impressive, the absolute difference was approximately 0.45 points on an 18-point clinical rating scale.
Furthermore, patients receiving the medication continued to decline on average.
That distinction deserves attention.
Families want to preserve conversations, relationships, independence, and quality of life.
They want their loved ones to remember names, recognize familiar faces, and participate in everyday activities.
Therefore, the relevant question is not simply whether a drug changes a laboratory or imaging measurement.
The question is whether treatment produces meaningful benefits that justify its risks and burdens.
Some patients may value modest slowing. However, the limited average benefit must be considered alongside potentially serious complications.
The August 2026 BMJ Study Questions Long-Term Effectiveness
In August 2026, BMJ Neurology Open published an analysis examining long-term outcomes from lecanemab and donanemab trials.
Researchers compared cognitive decline during the original controlled treatment periods with decline during subsequent open-label extensions.
Their findings raised serious concerns.
For both medications, the rate of cognitive decline became steeper during extended treatment.
Furthermore, those later decline rates approached the rates observed in the original placebo groups.
These results challenge claims that continued amyloid removal necessarily produces increasing long-term clinical benefits.
Importantly, the analysis used published trial results and statistical modeling. Because the extension periods lacked concurrent placebo controls, the findings cannot establish that either drug directly accelerated Alzheimer's progression.
Nevertheless, the study raises a legitimate question:
If patients continue to deteriorate at rates approaching those of placebo groups, how durable is the clinical benefit of continued amyloid removal?
That question deserves a clear answer.
The 2023 Neurology Study Raises Concerns About Brain Shrinkage
Another important investigation appeared in Neurology in 2023.
Researchers reviewed 145 clinical trials and included 31 in their final analysis.
Their largest comparisons involved more than 10,000 participants.
The investigators examined brain-volume changes associated with anti-amyloid medications.
They identified accelerated volume changes involving the whole brain, hippocampus, or ventricles, depending on the drug class.
Importantly, the researchers reported greater whole-brain volume loss in trial data involving lecanemab and donanemab.
They also identified a relationship between ventricular enlargement and amyloid-related imaging abnormalities.
These findings deserve serious investigation.
Brain-volume loss often accompanies neurodegenerative disease. However, researchers have not conclusively established whether every treatment-associated volume change represents permanent neuronal destruction.
Nevertheless, the findings raise important questions about long-term brain health.
When a medication produces modest clinical benefits while raising concerns about brain-volume changes, patients deserve complete transparency.
The Serious Risks of Alzheimer's Infusion Drugs
Both Leqembi and Kisunla carry warnings about potentially serious neurological complications.
These include brain swelling and bleeding, collectively called amyloid-related imaging abnormalities, or ARIA.
Some patients experience no noticeable symptoms.
However, others develop headaches, confusion, dizziness, visual disturbances, or neurological changes.
Rare complications can be life-threatening or fatal.
Consequently, treatment requires careful screening, informed consent, and repeated MRI monitoring.
Certain genetic factors, including APOE4, can increase the risk of complications.
These concerns become especially important when the expected benefit involves modest slowing rather than cognitive recovery.
At The Carroll Institute, we believe the risk-benefit balance of amyloid-targeting infusions deserves substantial scrutiny.
Removing plaque is not the same as restoring brain health.
Patients considering these medications should discuss their individual circumstances with a neurologist and should not discontinue prescribed treatment without medical guidance.
Why Precision Medicine Offers a Different Approach
Precision Medicine begins with the individual patient.
Instead of assuming that everyone with cognitive decline has the same underlying problems, clinicians investigate each person's medical history, risk factors, and relevant clinical findings.
For example, one patient may have significant insulin resistance.
Another may struggle with untreated sleep apnea.
A third may have vascular disease, nutritional deficiencies, or medication-related cognitive difficulties.
Many patients experience several contributing problems simultaneously.
Consequently, a single standardized intervention cannot address every possible combination.
A Precision Medicine approach seeks to identify actionable problems and develop an individualized plan.
Importantly, this does not mean every abnormal laboratory result causes Alzheimer's disease.
Nor does correcting metabolic or inflammatory abnormalities guarantee reversal of established Alzheimer's pathology.
However, addressing treatable contributors can improve overall health and sometimes cognitive performance.
That opportunity should not be overlooked.
How the Carroll Cognitive Method™ Identifies and Addresses Contributing Factors
At The Carroll Institute, we combine Precision Medicine, Functional Medicine, and Functional Neurology through the Carroll Cognitive Method™.
Our goal is to identify factors affecting cognitive health and develop a personalized program that addresses problems that may respond to treatment.
1. Precision Medicine: Investigating the Individual
First, we examine the patient's medical history, cognitive symptoms, and relevant clinical findings.
Depending on the situation, evaluation may include metabolic health, vascular risk, sleep disorders, nutritional deficiencies, medication effects, and selected genetic information.
Rather than assuming amyloid explains every symptom, we investigate the broader clinical picture.
2. Functional Medicine: Addressing Physiological Contributors
Next, we examine how different body systems influence brain health.
For example, poor sleep can worsen memory and concentration.
Likewise, nutritional deficiencies and poorly controlled metabolic conditions can interfere with cognitive performance.
Therefore, we develop individualized strategies that address clinically relevant health problems.
These may include nutrition, exercise, sleep management, and appropriate medical coordination.
3. Functional Neurology: Supporting Neuroplasticity
Finally, we incorporate targeted neurological rehabilitation.
Depending on the patient's needs, this may include cognitive exercises, movement, balance activities, and other individualized interventions.
These strategies draw on neuroplasticity, the brain's ability to adapt through learning and repeated activity.
Neuroplasticity can support rehabilitation and functional adaptation. However, it does not guarantee reversal of established Alzheimer's pathology.
Together, these approaches allow us to investigate potentially treatable contributors while supporting cognitive function as effectively as possible.
Our Goal Is Improvement, Not Simply Slower Decline
Families rarely ask how much amyloid remains in the brain.
Instead, they ask whether their loved one can remember conversations, recognize familiar people, and maintain independence.
Those are the outcomes that matter.
At The Carroll Institute, our goal is to pursue measurable cognitive improvement whenever possible.
We report that more than 90% of patients who complete our program demonstrate measurable cognitive improvement.
This figure reflects our clinic's reported experience. It does not represent a result from an independently verified randomized clinical trial of the Carroll Cognitive Method™.
To interpret that percentage properly, patients should understand which tests were used, how improvement was defined, how many patients completed the program, and whether improvements persisted.
We believe transparency matters.
No responsible clinician can promise that Alzheimer's disease will reverse.
Nevertheless, clinicians should actively investigate treatable contributors rather than assume that every cognitive symptom must inevitably worsen.
The goal should be to improve function wherever possible—not simply accept deterioration without further investigation.
Why Early Intervention Matters
Time matters when someone experiences cognitive decline.
As symptoms progress, patients may lose abilities that become increasingly difficult to recover.
Therefore, early evaluation offers important advantages.
Clinicians may identify sleep disorders, nutritional deficiencies, metabolic conditions, or medication effects that contribute to cognitive difficulties.
Furthermore, patients may benefit from exercise, cognitive engagement, social interaction, and rehabilitation strategies that support everyday functioning.
These interventions cannot guarantee recovery from Alzheimer's disease.
However, delaying appropriate evaluation can mean missing opportunities to address treatable problems.
Memory loss is common. Persistent or progressive memory loss should never be dismissed as normal aging.
Frequently Asked Questions
Is amyloid plaque the primary cause of Alzheimer's disease?
Amyloid contributes to Alzheimer's pathology, but the disease also involves abnormal tau, neuroinflammation, immune dysfunction, metabolic changes, and neuronal injury. Researchers continue to investigate how these processes interact and which mechanisms offer the best treatment targets.
What role do glial cells play in Alzheimer's disease?
Microglia are specialized immune cells that help protect the brain. However, persistent activation can contribute to inflammation, synaptic damage, and neuronal injury. Researchers are investigating how microglial dysfunction influences Alzheimer's progression.
What is microglial priming?
Microglial priming occurs when previous inflammatory or stressful conditions change how microglia respond to future challenges. Aging, metabolic dysfunction, and other factors may influence this process.
Do Leqembi and Kisunla reverse Alzheimer's disease?
No. Their pivotal trials demonstrated modest slowing of decline in selected patients with early Alzheimer's disease. Neither medication demonstrated reversal of established Alzheimer's dementia.
Can Alzheimer's infusion drugs cause brain shrinkage?
A 2023 meta-analysis identified accelerated brain-volume changes associated with several anti-amyloid therapies, including findings involving lecanemab and donanemab. However, researchers have not established whether every observed volume change represents permanent neuronal loss.
Can treating inflammation improve cognitive function?
Treating medical conditions that contribute to inflammation or cognitive symptoms may improve overall health and sometimes cognition. However, evidence does not establish that reducing inflammation alone reliably reverses confirmed Alzheimer's dementia.
What makes the Carroll Cognitive Method™ different?
The Carroll Cognitive Method™ combines Precision Medicine, Functional Medicine, and Functional Neurology. Rather than concentrating exclusively on amyloid plaque, the program investigates potentially modifiable contributors and incorporates individualized neurological rehabilitation.
The Future of Alzheimer's Care Must Look Beyond Amyloid
For decades, Alzheimer's research concentrated heavily on amyloid plaque.
Yet removing plaque has not produced the cognitive recovery that patients and families desperately want.
Meanwhile, research increasingly highlights the importance of neuroinflammation, glial cell activation, metabolic dysfunction, mitochondrial health, and other interacting processes.
The August 2026 BMJ Neurology Open analysis raises questions about sustained long-term benefits from anti-amyloid medications.
The 2023 Neurology meta-analysis raises concerns about treatment-associated brain-volume changes.
Together, these findings strengthen the argument for looking beyond amyloid alone.
At The Carroll Institute, we believe patients deserve a more comprehensive approach.
They deserve an investigation into the factors affecting their brain.
They deserve individualized care.
And they deserve a treatment strategy that aims to support meaningful cognitive function whenever possible.
Because slowing the decline is not the same as improving the patient.
And we believe Alzheimer's care must aim higher.
Schedule a Discovery Call With The Carroll Institute
If you or someone you love is experiencing memory loss, Mild Cognitive Impairment, Alzheimer's disease, or other cognitive difficulties, we encourage you to explore whether an individualized evaluation may be appropriate.
At The Carroll Institute in Sarasota, Florida, the Carroll Cognitive Method™ combines Precision Medicine, Functional Medicine, and Functional Neurology to investigate contributing factors and support cognitive health.
Schedule a complimentary discovery call to learn whether our approach may be appropriate for your situation.
Schedule Your Complimentary Discovery Call
Or call 941-350-7722.
Learn more about the Carroll Cognitive Method™.
Sources and References
- Dwivedi AK, Imbimbo BP, Abanto J, Espay AJ. Comparison of double-blind and open-label decline rates in lecanemab and donanemab trials in Alzheimer's disease. BMJ Neurology Open. 2026. Read the study.
- Alves F, Kalinowski P, Ayton S. Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs: A Systematic Review and Meta-analysis. Neurology. 2023. Read the study.
- van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023. Read the study.
- Sims JR, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023. Read the study.
- Perlmutter D. Brain Defenders: Harness the Power of Your Immune Cells to Protect Your Brain for Life. Chapters 2–4. Background discussion of neuroinflammation, microglial activation, mitochondrial dysfunction, and immunometabolism.
- EVANTHEA Precision Medicine Trial. ClinicalTrials.gov. View the trial record.
- National Institute on Aging. What Happens to the Brain in Alzheimer's Disease? Read the overview.
Medical Disclaimer
This information is provided for educational purposes only and is not intended as medical advice. Individual outcomes vary. No specific result can be guaranteed. Patients should consult a qualified healthcare professional regarding their individual medical situation.
Reviewed by: Dr. Garland Glenn, DC, PhD, IFM, AFMC
Location: Sarasota, Florida
Last Updated: November 15, 2026
WordPress note: If your page templa
Dr. Garland Glenn, DC, PhD, IFM, AFMC
Founder & Clinical Director, The Carroll Institute — Sarasota, FL
Dr. Garland Glenn is a board-certified chiropractic physician and functional medicine practitioner specializing in cognitive health, neurodegeneration, and root-cause medicine. Certified as an AFMC (Advanced Functional Medicine Clinician) and Institute for Functional Medicine (IFM) trained, he has also completed over 500 hours of advanced training in Functional Neurology under Dr. Ted Carrick, founder of the Carrick Institute. Dr. Glenn has also completed Post Graduate training through Harvard Medical School.
At The Carroll Institute, Dr. Glenn leads Sarasota’s only ReCODE-certified Functional Neurology program, helping patients reverse or prevent cognitive decline through the Bredesen ReCODE Protocol, neuroplasticity exercises, and personalized functional medicine care.
Learn more about his background and approach at About Dr. Garland Glenn.
– schedule now –
free discovery call
To help you get started, we offer a free 20-minute Discovery Phone Consultation. During this call, you will be able to talk with one of our Certified Brain Health Coaches about what going on with you or your loved one and find out if we can help. Please review our FAQs prior to scheduling your free call. We look forward to talking with you soon and helping you Save Your Brain.
(yes, it’s totally free!)
ReCODE® is a registered program developed by Dr. Dale Bredesen and licensed through Apollo Health. Dr. Garland Glenn is a certified ReCODE practitioner.